TY - JOUR T1 - New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016 JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1186/s40425-017-0253-2 VL - 5 IS - 1 SP - 50 AU - Prasad S. Adusumilli AU - Edward Cha AU - Mark Cornfeld AU - Thomas Davis AU - Adi Diab AU - Thomas W. Dubensky, Jr. AU - Elizabeth Evans AU - Jane L. Grogan AU - Bryan A. Irving AU - Rom S. Leidner AU - Shane A. Olwill AU - Patrick Soon-Shiong AU - Frederic Triebel AU - David Tuck AU - Adrian Bot AU - Roger D. Dansey AU - Charles G. Drake AU - Gordon J. Freeman AU - Ramy Ibrahim AU - Salil Patel AU - Daniel S. Chen Y1 - 2017/12/01 UR - http://jitc.bmj.com/content/5/1/50.abstract N2 - This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.Abbreviations:AEAdverse event(s)APCAntigen presenting cell(s)CARChimeric antigen receptor(s)CITNCancer Immunotherapy Trials NetworkCRCColorectal cancerDCDendritic cell(s)DLTDose-limiting toxicityDNRDominant negative receptorEGFREpidermal growth factor receptorFDAFood and Drug AdministrationHNSCCHead and neck squamous cell carcinomaIDOIndoleamine 2,3-dioxygenaseIHCImmunohistochemistryKIRKiller cell immunoglobulin-like receptor(s)LADDLive-attenuated double-deleted Listeria monocytogenesmAbMonoclonal antibodyMDSCMyeloid-derived suppressor cell(s)MHCMajor histocompatibility complexMSSMicrosatellite stableNKNatural killerNSCLCNon-small cell lung cancerPBMCPeripheral blood mononuclear cellsPFSProgression-free survivalPRPartial responseRCCRenal cell carcinomaSEMA4DSemaphorin 4DSITCSociety for Immunotherapy of CancerTCBT cell-engaging bispecific antibodiesTEAETreatment-emergent adverse event(s)TILTumor infiltrating lymphocyte(s)TLRToll-like receptorTMETumor microenvironmentTregRegulatory T cell(s) ER -